Combination Therapy For Endovascular Procedures

Product Quick Finder

Choose a category or subcategory

Undress the full metal jacket

Leave almost nothing behind by using our proven SeQuent® Please OTW DCB in combination with our spot stenting device VascuFlex® Multi-LOC.

SeQuent® Please OTW: A fruitful formulation

Paclitaxel with a drug dose of 3 μg/mm²

  • Proven and effective drug dose1
  • Homogeneous coating even in the balloon folds2

Resveratrol with positive characteristics

  • Naturally occurring, plant based substance
  • Anti-inflammatory, antioxidant & anti-hypertensive3,4
  • Facilitates drug transfer into vessel wall2

CONSEQUENT randomized controlled trial

  • 153 patients (78 DCB vs. 75 POBA)
  • Rutherford 2-4 (95 % Grade 3-4)
  • Diameter stenosis pre-procedure: 76.6 ± 18.1 %
  • TASC C/D lesions: 23.5 %
  • Mean lesion length 13.2 ± 10.4 cm
  • Positive remodeling (LLL <0.00 mm) in DCB group: 36.5 %
  • Predilatation: in only 55.6 % of cases
  • Bailout stenting: 16.3 % (similar in both groups)
  • Primary endpoint: 6-month angiographic late lumen loss
  • Secondary endpoints: TLR, binary restenosis (> 50 %, PSVR > 2.4), walking distance, ABI at 6, 12 and 24 months

VascuFlex® Multi-LOC: Spot your lesions with short stents only!

  • Six short stents on one delivery system
  • Cover lesions only where it is really needed
  • Maintain natural vessel movement
  • Avoid full metal jackets

Features

  • Short self-expanding Nitinol stents of 13 mm length each
  • Stents with high radial force for highly calcified lesions2
  • 5-8 mm stent diameters for SFA and popliteal arteries
  • 0.035” guidewire compatibility; 6F sheath compatibility

LOCOMOTIVE all comers registry: Preliminary 12-month results12

  • 75 patients
  • Rutherford 2-5 (95 % Grade 3-5)
  • Lesion treated in SFA & P1-P3 (mean RVD: 5.6 ± 0.7 mm)
  • Mean lesion length 14.5 ± 9.0 cm
  • Degree of stenosis: 88.4 %
  • TASC C/D lesions: 51.1 %
  • Primary endpoint: TLR at 6 months
  • Secondary endpoints: TLR at 12 months; walking distance, ABI, patency, Rutherford, amputation at 6 and 12 months

1 Katsanos K et al. in J Endovasc Ther. 2016 Apr;23(2):356-70
2 Data on file at B. Braun
3 Ciccone G et al. in Curr Med Chem. 2013;20(10):1323-31
4 Magyar K et al. Clin Hemorheol Microcirc. 2012;50(3):179-87
5 Tepe G et al. Cardiovasc Intervent Radiol 2017;doi:10. 1007/s00270-017-1713-2
6 Schröder H Catheterization and Cardiovascular Interventions, Volume 86, Issue 2 August 2015 Pages 278-286
7 Werk M et al. Circ Cardiovasc Interv. 2012;5(6):831-840
8 Scheinert D et al. JACC Cardiovasc Interv. 2014;7(1):10-19
9 Zeller T et al. JACC Cardiovasc Interv. 2015;8(12):1614-1622
10 24-month results presented at LINC 2018
11 Amendt K et al. Vasa 2017;46(6):1-10
12 12-month results presented at LINC 2018

B. Braun Melsungen AG
Sieversufer 8
12359 Berlin
Germany